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globulin mucin 3 (TIM-3) or other checkpoints,4 
and recently identified mechanisms of primary 
resistance to PD-1–PD-L1 blockade, which include 
transcriptional signatures in the tumor microen-
vironment (innate anti–PD-1 resistance signature, 
or IPRES5) and the presence of somatic differ-
ences in tumor cells (constitutive activation of 
β-catenin6 or loss of PTEN7) that inhibit the ac-
tivation and recruitment of T cells to the tumor 
microenvironment.
Together, these observations shed further light 
on the possible mechanisms of treatment failure 
in patients who do not have a response to the 
current checkpoint antibodies, beyond the limited 
ability of the current Food and Drug Administra-
tion–approved PD-L1 companion immunohisto-
chemical assays to identify patients who will or 
will not have a response.8 At the same time, the 
results also raise some important questions. Are 
they applicable to PD-1 resistance in other tumor 
types? Are there rational approaches to salvage 
therapy, such as the activation of downstream 
interferon pathways by cytosolic double-stranded 
DNA, which directly activates the stimulator of 
interferon genes (STING)9 in a JAK-independent 
fashion and could remedy some of the immune 
escape mechanisms detailed in the article? And 
could the mutated B2M-induced lack of expres-
sion of MHC class I be overcome by MHC class 
II–mediated CD4 T-cell recognition of tumor 
epitopes or by cross-presentation by stromal 
myeloid cells, leading to bystander elimination 
of antigen-loss variants?10
The ability of whole-exome sequencing to 
identify mechanisms of both innate and acquired 
resistance has potential clinical applications. As 
our knowledge of the host–tumor interactions at 
both the genomic and biologic levels increases, 
we inch closer to the time when extensive ge-
nomic analysis coupled with immune profiling 
will be applied to patients with cancer at the 
time of diagnosis and at relapse, to aid in selec-
tion of the combination therapy that is most 
likely to bring about eradication of an individual 
patient’s tumor — the ultimate goal of precision 
medicine.
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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Safety of Long-Acting Beta-Agonists in Children with Asthma
Andrew Bush, M.B., B.S., M.D., and Urs Frey, M.D., Ph.D.
Has there ever been more of a Jekyll-and-Hyde 
protein than the airway β2 receptor? Short-acting 
beta-agonists give rapid relief from broncho-
spasm, but their overuse is a factor in asthma-
related deaths, and the less-selective agents have 
been associated with epidemics of patients dying 
during acute asthma attacks. In children with 
uncontrolled asthma, the Best Add-on Therapy 
Giving Effective Responses (BADGER) study 
showed that the addition of long-acting beta-
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agonists (LABAs) was more effective than in-
creasing the dose of inhaled glucocorticoids in 
controlling asthma,1 but the accompanying edi-
torial2 highlighted the limited evidence regarding 
the safety of this approach and instead favored 
increasing the dose of inhaled glucocorticoids. It 
was clear that further safety studies were needed 
if the BADGER approach were to be adopted.
Thus, it is reassuring to see in the Journal a 
report of a large, well-conducted trial involving 
children that was mandated by the Food and 
Drug Administration (FDA) and that shows no 
excess of serious asthma events in children re-
ceiving a combination inhaler containing fluti-
casone propionate and salmeterol.3 Interestingly, 
as with the corresponding trial involving adults,4 
there was some evidence of efficacy in terms of 
secondary outcomes for LABAs. The obvious 
strengths of the trial are the large numbers 
studied (>3000 participants in each group) and 
the reassuringly low number of adverse events. 
Although intercenter differences in treatment 
policies and definitions of asthma attacks are 
always difficult to control for, it is hard to imagine 
a better trial being performed in the near future. 
There are weaknesses in the trial; although it is 
large and well done, it does not completely rule 
out an adverse effect from LABAs. However, it 
does go a long way toward ruling out a class 
effect of these medications, but the findings 
should not be extrapolated uncritically to other 
medications in this class.
No clinical trial is perfect, and the trial con-
ducted by Stempel et al. is no exception to that 
rule. To achieve a “real-world setting,” medica-
tion use at baseline was not optimized. It may 
be that some children were being overtreated, 
and therefore the safety of LABAs in these chil-
dren was in the context of overtreatment with 
inhaled glucocorticoids, and the conclusion might 
be different with an appropriate dose. In addi-
tion, this trial was predicated on the assump-
tion that the risk factors for asthma-related 
death (the most pressing safety concern) and 
asthma attacks are the same. Exacerbations are 
related to asthma-control status, history of ex-
acerbations, environmental triggers, and season-
al, genetic, and immunologic modifying risks,5 
but the predominant causes of asthma-related 
death6 are lack of access to health care (45% of 
the participants had not attempted to seek pro-
fessional help), lack of personal action plans, 
underuse of glucocorticoids, overuse or inappro-
priate use of bronchodilators, underestimation 
of asthma severity by treating doctors and by 
parents, lack of objective measures of airway 
obstruction, and nonadherence to the regimen, 
including drug and alcohol use by caretakers. 
Particularly in children and young people, the 
poor recognition of the risk of an adverse out-
come was an important avoidable factor. The pres-
ent trial controlled for many of these factors, 
and given the rarity of asthma-related deaths, a 
vastly larger study, which is unlikely ever to be 
practicable, would be needed if death was the 
end point. Nonetheless, a trial in which (we are 
happy to note) there were no asthma-related 
deaths in either group cannot rule out a small 
effect on asthma-related deaths that might have 
appeared in a much larger study.
What are the implications of this report for 
clinical practice? Clearly, the safety of a medica-
tion is not necessarily the best indication for its 
prescription. Most children will have their asthma 
controlled by low-dose inhaled glucocorticoids 
if taken regularly through an appropriate device. 
If asthma is not controlled, rather than uncriti-
cally adding on further therapies, pediatricians 
are advised to first check the adequacy of tech-
nique with the medication-delivery device, make 
sure that patients and children understand treat-
ment and action plans, and at a minimum, verify 
whether the family is collecting enough prescrip-
tions to cover the need for regular medications 
— something achieved by only one in six fami-
lies in one study.7
There is no evidence for the use of a com-
bined inhaler as first-line preventive therapy in 
children, and this fact needs to be emphasized 
because such use is increasingly creeping into 
practice.8,9 Monotherapy with a LABA in a child 
should be considered medical negligence, and we 
suggest that single LABA inhalers should carry a 
warning to that effect, as required in the United 
States by the FDA in 2010.10 However, for the 
unusual child with asthma who needs more 
than low-dose inhaled glucocorticoids to control 
the disease or who has persistent, objectively 
documented, variable airf low obstruction, the 
present trial provides reassuring evidence that 
combination inhalers containing a LABA and an 
inhaled glucocorticoid are safe.
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